Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults
Source: View publication →
In the phase 3 RENOIR trial, a single dose of the bivalent RSVpreF vaccine safely and effectively prevented RSV-associated lower respiratory tract illness in adults 60 years of age and older.
Key Findings
Study Design
Study Limitations
Clinical Significance
The RENOIR trial was a landmark study that proved the clinical utility of stabilizing the highly immunogenic prefusion F conformation of RSV. By demonstrating high efficacy against symptomatic lower respiratory tract disease in older adults, the trial directly supported the FDA approval of Abrysvo (RSVpreF). Because RSV causes significant seasonal morbidity, hospitalizations, and mortality in populations aged 60 and older, having a safe, efficacious vaccine addresses a major decades-old unmet public health need.
Historical Context
For over 60 years, developing a safe and effective vaccine against RSV remained elusive. The failure of a formalin-inactivated RSV vaccine in the 1960s, which paradoxically caused enhanced respiratory disease and fatalities in children, severely chilled subsequent vaccine research. It was not until the 2010s, when NIH structural biologists successfully mapped and stabilized the metastable prefusion conformation of the RSV F protein—the primary target for highly neutralizing antibodies—that development accelerated. The simultaneous publication of RENOIR (Pfizer's RSVpreF) and AReSVi-006 (GSK's RSVPreF3) in 2023 marked the historic culmination of this effort, breaking the long-standing dry spell in RSV prophylaxis.
Guided Discussion
High-yield insights from every perspective
How does targeting the prefusion F protein of RSV confer a more robust and neutralizing immune response compared to targeting the postfusion conformation?
Key Response
The F (fusion) protein is responsible for viral entry into host cells. The prefusion conformation displays highly conserved, highly neutralization-sensitive epitopes (such as Site 0) that are structurally lost once the protein triggers and refolds into the postfusion state. Antibodies generated against the stabilized prefusion F protein are significantly more potent at neutralizing the virus, making this structural biology breakthrough the cornerstone of modern RSV vaccines.
When discussing the bivalent RSVpreF vaccine with a 65-year-old patient who has COPD and heart failure, how do you navigate shared clinical decision-making regarding co-administration with seasonal influenza and COVID-19 vaccines?
Key Response
Patients with underlying cardiopulmonary comorbidities are at the highest risk for severe RSV lower respiratory tract illness (LRTI) and stand to benefit the most. Co-administration is clinically safe and practically recommended to maximize adherence before the winter respiratory season, but residents must counsel patients that co-administration can occasionally result in slightly lower immunogenicity or increased local reactogenicity, balancing these minor risks against the danger of delayed or missed vaccination.
The RSVpreF vaccine is bivalent, covering both RSV A and RSV B subgroups. Given the historical difficulty in achieving balanced immunogenicity, how does the inclusion of both subgroups impact the prevention of RSV-associated LRTI, and what does the RENOIR trial data reveal regarding breakthrough infections by subtype?
Key Response
RSV A and B co-circulate and can alternate dominance seasonally. A bivalent approach ensures broad protection against both strains. Fellows must critically evaluate the trial's subgroup analyses to determine if vaccine efficacy significantly differed between subtypes and consider how potential subtype mismatch could influence seasonal outbreaks in highly vulnerable populations, such as lung transplant recipients or patients with advanced structural lung disease.
The FDA approved the RSVpreF vaccine but noted a potential rare risk of Guillain-Barre syndrome (GBS) and atrial fibrillation. How should attendings contextualize these rare safety signals when framing the number needed to vaccinate (NNV) to prevent severe RSV hospitalization in clinical practice?
Key Response
Attendings must weigh the robust efficacy in preventing severe lower respiratory tract illness against rare but serious adverse events. Teaching points should emphasize risk-stratification: the NNV to prevent hospitalization is highly favorable in patients with severe cardiopulmonary disease (where RSV triggers fatal exacerbations), justifying a strong recommendation, whereas a more nuanced shared decision-making approach is appropriate for healthy 60-year-olds with lower baseline risk.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The RENOIR trial utilized a case-driven, event-triggered design rather than a fixed follow-up period to determine its primary efficacy endpoints. What are the statistical advantages and potential biases of this approach in evaluating a seasonal respiratory virus vaccine?
Key Response
Event-driven designs maximize statistical power by ensuring a sufficient number of primary endpoints (e.g., severe RSV LRTI) are captured, which accelerates trial completion. However, this approach can introduce temporal bias if the follow-up period truncates midway through a respiratory season, potentially misestimating the waning of immunity and the long-term durability of vaccine efficacy across multiple distinct seasons.
The primary endpoint in the RENOIR trial relied on specific clinical symptoms combined with PCR-confirmed RSV. How might the sensitivity of these symptom definitions for lower respiratory tract illness (LRTI) impact the calculated vaccine efficacy, and what methodological gaps exist regarding endpoint ascertainment in frail or cognitively impaired older adults?
Key Response
Subjective symptom reporting in older adults, especially those with baseline dyspnea from conditions like COPD or cognitive impairment, can lead to misclassification bias. A critical reviewer would flag that if the case definition requires acute symptoms often masked by chronic illness, the trial might systematically miss cases or artificially inflate vaccine efficacy against narrowly defined LRTI compared to broader, real-world all-cause RSV hospitalizations.
Based on the RENOIR trial's efficacy data and subsequent real-world cost-effectiveness analyses, should ACIP guidelines formally transition from a 'shared clinical decision-making' recommendation to a universal age-based recommendation (e.g., all adults >75 or >60 with risk factors), and how do these findings compare to existing influenza guidelines?
Key Response
Initially, ACIP recommended RSV vaccines for adults >60 based on shared clinical decision-making due to high cost per QALY and the rare GBS signal. Evaluating RENOIR's robust protection against LRTI alongside the substantial disease burden has led to guideline updates (e.g., universally recommending it for >75 and at-risk >60). The committee must constantly weigh NNV, durability of protection, and healthcare economics to justify moving from individualized to categorical recommendations, similar to established universal age-based influenza vaccine guidelines.
Clinical Landscape
Noteworthy Related Trials
AReSVi-006 Trial
Tested
RSVPreF3 OA vaccine
Population
Adults 60 years of age or older
Comparator
Placebo
Endpoint
RSV-associated lower respiratory tract disease (LRTD)
ConquerRSV Trial
Tested
mRNA-1345 RSV vaccine
Population
Adults 60 years of age or older
Comparator
Placebo
Endpoint
RSV-associated LRTD with at least 2 symptoms
MATISSE Trial
Tested
Bivalent RSVpreF vaccine
Population
Pregnant women at 24 to 36 weeks gestation
Comparator
Placebo
Endpoint
Severe medically attended RSV-associated LRTD in infants
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis